Clinical Trials Logo

Filter by:
NCT ID: NCT01323205 Completed - Schizophrenia Clinical Trials

Investigation of the Safety, Tolerability and Potential Therapeutic Effects of JNJ-40411813 in Patients With Schizophrenia

Start date: May 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study is to explore the safety, tolerability, and potential clinical efficacy of JNJ 40411813 in schizophrenic patients.

NCT ID: NCT01322490 Completed - Clinical trials for Prostate Cancer Metastatic

A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer

Prospect
Start date: November 28, 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether PROSTVAC alone or in combination with GM-CSF is effective in prolonging overall survival in men with few or no symptoms from metastatic, castrate-resistant prostate cancer.

NCT ID: NCT01322451 Completed - Healthy Clinical Trials

Oral Bioavailability of Two Solid Formulations of GLPG0259.

Start date: November 2010
Phase: Phase 1
Study type: Interventional

The purpose of the study is to evaluate the relative bioavailability of two solid oral formulations of GLPG0259 administered after a meal.

NCT ID: NCT01321554 Completed - Thyroid Cancer Clinical Trials

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)

SELECT
Start date: March 17, 2011
Phase: Phase 3
Study type: Interventional

This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 study to compare the progression free survival, overall response rate (ORR) and safety of participants treated with lenvatinib 24 mg by continuous once daily oral dosing versus placebo. The study is conducted in 3 phases: a Prerandomization Phase (screening and baseline period), a Randomization Phase (double-blind treatment period), and an Extension Phase (Optional Open Label (OOL) Lenvatinib Treatment Period and a follow-up period).

NCT ID: NCT01321541 Completed - Clinical trials for Diffuse Large B-cell Lymphoma

Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant

PIX-R
Start date: April 20, 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy of Pixantrone + Rituximab compared to Gemcitabine + Rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), or follicular grade 3 lymphoma.

NCT ID: NCT01320176 Completed - HIV Clinical Trials

Study to Evaluate the Dosage and Safety of Two Intramuscular Injections of an Investigational Clade B HIV Vaccine

Start date: October 2010
Phase: Phase 1
Study type: Interventional

This study aimed to evaluate the safety and reactogenicity of two intramuscular injections of two different dosages of an investigational clade B HIV vaccine.

NCT ID: NCT01320137 Completed - Immunological Tests Clinical Trials

Study in Allergic Adults to Support the Development of Immunological Assays

Start date: March 2011
Phase: Phase 4
Study type: Interventional

The purpose of this study is to develop and characterize immunological assays on blood samples.

NCT ID: NCT01319604 Completed - Glaucoma Clinical Trials

SENSIMED Triggerfish

Start date: March 2011
Phase: N/A
Study type: Interventional

The purpose of the investigation is to investigate the relationship between the study device output and tonometric assessments.

NCT ID: NCT01319487 Completed - Clinical trials for Diabetic Macular Edema

Safety and Efficacy Study of Topical Administration of FOV2304 (High Dose or Low Dose) for the Treatment of Center-involving Clinically Significant Macular Edema Associated With Diabetic Retinopathy

Start date: May 2011
Phase: Phase 2
Study type: Interventional

The purpose of the study is to determine whether concentrations of FOV2304 (high dose or low dose) administered in the eye are more effective than placebo in treating patients with diabetic macular edema, following 12 weeks of treatment.

NCT ID: NCT01318941 Completed - Clinical trials for Diabetic Macular Edema

Observe the Effectiveness and Safety of Ranibizumab in Real Life Setting

LUMINOUS
Start date: March 2011
Phase: N/A
Study type: Observational

This study will describe the long-term safety and effectiveness, treatment patterns,and patient reported quality of life associated with ranibizumab treatment in routine clinical practice for all approved indication included in the local product label.